Why the study?
Does ticagrelor reduce cardiovascular death, MI, or ischemic stroke compared to clopidogrel in patients with symptomatic peripheral artery disease?
Does ticagrelor reduce cardiovascular death, MI, or ischemic stroke compared to clopidogrel in patients with symptomatic peripheral artery disease?
Ticagrelor monotherapy is not superior to clopidogrel in preventing cardiovascular events in patients with symptomatic peripheral artery disease.
Ticagrelor not superior to clopidogrel in symptomatic PAD; leaves open optimal antiplatelet choice pending higher-level evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Aimee L. Vos (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: